The Global Parkinson’s Disease (PD) Market is Expected to Decline From $3.4 Billion in 2012 to $2.9 Billion By 2019. For more information please visit: http://www.marketresearchreports.com/gbi-research/parkinsons-disease-therapeutics-market-2019-pipeline-shows-shift-towards-long-term

1. Category : Diseases / Healthcare
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

2. Introduction to Report
 Launch Date: December 15, 2013
 Number of Pages: 130
 Geography Coverage: Global
 Available Format: PDF
Price For Single User License: USD 3,500
Price For Site License: USD 7,000
Price For Global User License: USD 10,500
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com

3. About the Report
Due to upcoming patent expirations for four
high-profile drugs, the global Parkinson’s
Disease (PD) market is expected to decline from
$3.4 billion in 2012 to $2.9 billion by 2019, at a
negative Compound Annual Growth Rate
(CAGR) of 2.3%.
www.MarketResearchReports.com

4. Research Findings
The latest report states that Parkinson’s Disease (PD)
drugs, such as Azilect (rasagiline mesylate), Stalevo
(levodopa, carbidopa, entacapone) and Comtan
(entacapone), will lose their patents by the end of the
forecast period. Generic alternatives for these treatments
have already been approved, which will result in further
market competition.
Additionally, the loss of patent for Mirapex (pramipexole
dihydrochloride) and Exelon (rivastigmine tartrate) in
2010 and 2012 will continue to halt future PD market
growth.
www.MarketResearchReports.com

5. Reasons to Buy
Understand the different levels of PD therapy from early-stage
to advanced
Understand the vast scope of the pipeline, including which
molecule types and mechanisms of action are prominent
Observe the trends in clinical trial duration and size amongst
clinical phases and molecule types, and use the clinical trial
failure rate analysis to assess the risk profiles of current and/or
future developmental programs for PD therapeutics
Observe the trends in clinical trial duration and size amongst
clinical Phases, between molecule types and mechanisms of
action, and use the clinical trial failure rate analysis to assess the
risk profiles of current and/or future developmental programs
for PD therapeutics
Assess the potential clinical and commercial impact of current
late-stage pipeline molecules on the PD therapeutics market
www.MarketResearchReports.com

6. Report Coverage
1. Introduction
2. Marketed Products
3. Pipeline for Parkinson’s Disease
4. Market Forecast to 2019
5. Deals and Strategic Consolidations
6. Appendix
For more details regarding Report coverage see the last slide
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com

7. Custom Research:
 Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let
us know your specific research requirements. Our goal
is to cater to your requirements be it for a custom
market research project, syndicated research report on
a specific market or industry sector, newsletter creation,
case study development or anything else related to
marketing research.
For Any Customization Related query Visit IdeaCenter @
http://www.marketresearchreports.com/idea-center
www.MarketResearchReports.com

8. How To Buy This Report?
Visit following URL to see Table of Content and
purchase this publication:
http://www.marketresearchreports.com/gbiresearch/parkinsons-disease-therapeutics-market2019-pipeline-shows-shift-towards-long-term
About Market Research Reports, Inc.
Market Research Reports provides a customized set
of reports from reputed Publishers, built on the
intelligence available within organizations and
leverages on our motto of “Intelligence Redefined”.
Contact : Amitava Sen
Email : info@marketresearchreports.com
Phone: +1 302-703-7787 (USA) +91-8762746600 (India)
www.MarketResearchReports.com